Viewing nowCombinationHyglyiam Tablets 50/850 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 202300849 · Approved 2023.03.13 · Insurance code 670609110
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medicine helps patients with type 2 diabetes improve blood sugar control when taken alongside diet and exercise. It assists in managing blood sugar more effectively through the combination of sitagliptin and metformin. Therefore, this medicine is used for the treatment of type 2 diabetes.
The dose of this medicine for antidiabetic therapy should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Patients who should not take this medicine under Precautions for Use). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see section 5. General Precautions under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Patients who should not take this medicine under Precautions for Use).
This medicine consists of two active ingredients, each helping to control blood sugar. Firstly, this medicine can cause rare but serious allergic reactions; if symptoms like skin rash, hives, or difficulty breathing occur, stop taking it immediately and consult a healthcare professional. Additionally, this medicine may induce pancreatitis, an inflammation of the pancreas, so if abdominal pain, vomiting, or severe abdominal discomfort occurs, you should visit a hospital promptly. It is important not to use this medicine in patients with impaired kidney function or those experiencing acute kidney injury, and regular kidney function tests should be conducted. Patients with heart diseases such as heart failure or acute myocardial infarction should also not take this medicine, and its use should be temporarily halted before and after surgeries or tests using radiocontrast containing iodine. The safety of this medicine has not been established in pregnant or breastfeeding women, nor in children under the age of 18, and therefore it should not be administered. This medicine can cause hypoglycemia, so particularly when used in combination with other hypoglycemic agents, blood sugar levels should be monitored closely, and symptoms of hypoglycemia should be observed carefully. Moreover, it may cause gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain; if symptoms are severe, medical consultation should be sought. Alcohol consumption may increase the risk of side effects from this medicine, so excessive drinking should be avoided during treatment. Finally, regular blood tests and kidney function tests should be performed during treatment to detect any anomalies early and manage them.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly sealed container to prevent exposure to air and moisture. It is best to maintain a storage temperature between 1 to 30 degrees Celsius to preserve the effectiveness of the medication.
Pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.